Physician profile
Elisha H Christianson
NPI 1609124528
$371,171.71
in general payments reported to CMS, 2019-2025
33 companies · $201K in 2025
The $201K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,569 · 2022: $3,701 · 2023: $34K · 2024: $131K · 2025: $201K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $183K · Consulting Fee: $71K · Travel and Lodging: $65K · Food and Beverage: $35K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K · Education: $839 · Honoraria: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $182,558.66 |
| Consulting Fee | $70,770.66 |
| Travel and Lodging | $64,633.07 |
| Food and Beverage | $35,317.43 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,523.00 |
| Education | $838.74 |
| Honoraria | $260.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $63,847.51 | 2021-2025 | Otezla, Otezla, Enbrel |
| E.R. Squibb & Sons, L.L.C. | $50,018.29 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $43,234.78 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Sun Pharmaceutical Industries INC. | $40,594.06 | 2021-2025 | Ilumya, Blu-U, Winlevi |
| Ucb, INC. | $39,223.66 | 2021-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $34,249.38 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24,520.17 | 2022-2025 | Spevigo |
| Galderma Laboratories, L.P. | $23,134.36 | 2021-2025 | Nemluvio, Aklief |
| Janssen Biotech, INC. | $13,341.44 | 2021-2025 | Tremfya |
| Pfizer INC. | $9,129.75 | 2021-2025 | |
| Abbvie INC. | $6,738.86 | 2021-2025 | |
| Dermavant Sciences, INC. | $4,392.17 | 2023-2024 | Vtama |
| Botanix Sb INC | $4,265.16 | 2025 | Sofdra |
| Eli Lilly and Company | $3,662.81 | 2023-2025 | Ebglyss, Olumiant |
| Genzyme Corporation | $3,374.50 | 2021-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,843.42 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $1,663.22 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $962.15 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $854.42 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sanofi-Aventis U.S. LLC | $369.96 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $350.00 | 2025 | Zoryve |
| Organon LLC | $324.61 | 2024-2025 | Vtama |
| Mayne Pharma Commercial LLC | $223.39 | 2023-2025 | |
| Paratek Pharmaceuticals, INC. | $178.32 | 2022-2025 | Nuzyra |
| Almirall LLC | $168.59 | 2022-2023 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $149.94 | 2021-2025 | Jublia, Duobrii, Siliq |
| Celgene Corporation | $123.59 | 2024 | Sotyktu |
| Epi Health, LLC | $89.94 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $43.17 | 2023-2024 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $36.43 | 2021-2023 | Valchlor |
| Genentech USA, INC. | $28.03 | 2024 | Xolair |
| Merck Sharp & Dohme LLC | $19.53 | 2022 | |
| Nabriva Therapeutics, Plc | $16.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisha Christianson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.